NVNeus Villamor

Neus Villamor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Neus Villamor has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Elias Campo

    Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

    8 shared publications
  • Dolors Colomer

    Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    7 shared publications
  • Emili Montserrat

    Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomédiques Agustí Pi i Sunyer (IDIBAPS), University of Barcelona, Spain

    4 shared publications
  • Armando López-Guillermo

    Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Calle Roselló 149-153, 08036 Barcelona, Spain; Department of Haematology, Hospital Clínic, Calle Villarroel 170, 08036 Barcelona, Spain; Universitat de Barcelona, Facultat de Medicina, Calle Casanova 143, 08036 Barcelona, Spain

    3 shared publications
  • Julio Delgado

    Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain

    3 shared publications
  • Marta Aymerich

    3 shared publications

Latest Publications

  • Genetic evolution in chronic lymphocytic leukaemia

    by Julio Delgado, Neus Villamor, Armando López-Guillermo, Elías Campo


  • Mutations in the Toll-like receptor/MYD88 pathway in young (≤50 years) CLL patients

    by Alejandra Martínez-Trillos, Magda Pinyol, Alba Navarro, Marta Aymerich, Pedro Jares, Manel Juan, María Rozman, Dolors Colomer, Julio Delgado, Eva Gine, et al.

  • NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12

    by Cristina López, Julio Delgado, Dolors Costa, Laura Conde, Gabriela Ghita, Neus Villamor, Alba Navarro, Maite Cazorla, Cándida Gómez, Amparo Arias, et al.


    • 1 July 2006
      • Vol. 91  (7) , 895-902

    Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.

    by Silvia Marcé, Míriam Molina-Arcas, Neus Villamor, F Javier Casado, Elias Campo, Marçal Pastor-Anglada, Dolors Colomer

    Nucleoside transporters might play a relevant role in the intracellular targeting of many nucleoside analogs used in anticancer therapy. Two gene families (SLC28 and SLC29) encode the two types of human nucleoside transporters, concentrative nucleoside transporter (CNT) and equilibrative nucleoside transporter (ENT) proteins. Chronic lymphocytic leukemia (CLL) cells express both SLC28- and SLC29-related mRNA, although transport function seems to be mostly related to ENT-type transporters. Here we have analyzed the role of nucleoside transporters in nucleoside-derived drug bioavailability and action in mantle cell lymphoma (MCL) cells. The relative amounts of hENT1 and hENT2-related mRNA and protein were analyzed in five MCL cell lines and 20 primary MCL tumors by real-time quantitative reverse transcriptase polymerase chain reaction and western blots. Cell viability, measured by annexin V-FITC staining, and nucleoside-derived drug transport were also studied. MCL cells express higher levels of hENT1 protein than do CLL cells, and a good correlation was found between protein and mRNA levels of hENT1, thus indirectly suggesting that hENT1 might be transcriptionally regulated in MCL cells. More importantly, a significant correlation between these two parameters, drug uptake and sensitivity to gemcitabine, was also observed. These results further support the concept that nucleoside transporters are implicated in the therapeutic response to nucleoside analogs, and suggest a particular and novel role for hENT1 in the genotoxic response to selected nucleoside analogs, such as gemcitabine, in MCL cells.


  • Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia

    by Carol Moreno, Neus Villamor, Dolors Colomer, Jordi Esteve, Rodrigo Martino, Josep Nomdedéu, Francesc Bosch, Armando López-Guillermo, Elías Campo, Jorge Sierra, et al.

    To investigate whether allogeneic stem-cell transplantation (allo-SCT) may overcome the negative impact of unmutated VH genes in the outcome of patients with chronic lymphocytic leukemia (CLL). We analyzed the outcome of patients who underwent SCT according to their VH mutational status. Thirty-four patients (14 allo-SCT and 20 autologous SCT [auto-SCT]) presented unmutated VH genes and 16 patients presented mutated VH genes (nine allo-SCT and seven auto-SCT). Tumoral burden pre-SCT was significantly higher in the allo-SCT patients independent of the VH mutational status. The risk of relapse was significantly higher after auto-SCT (5-year risk, 61%; 95% CI, 44% to 84%) than after allo-SCT (5-year risk 12%, 95% CI, 3% to 44%; P < .05). In the unmutated group, 13 of 20 auto-SCT and two of 14 allo-SCT patients experienced disease progression, with a risk of relapse at 5 years of 66% (95% CI, 48% to 93%) v 17% (95% CI, 5% to 60%), respectively (P = .01). These results show that allo-SCT may overcome the unfavorable effect of unmutated VH genes in patients with CLL.


  • Immunohistochemical analysis of ZAP‐70 expression in B‐cell lymphoid neoplasms

    by Joaquim Carreras, Neus Villamor, Lluís Colomo, Carol Moreno, Santiago Ramón Y Cajal, Marta Crespo, Frederic Tort, Francesc Bosch, Armando López‐Guillermo, Dolors Colomer, et al.

    ZAP‐70 is a tyrosine kinase that participates in early B‐cell differentiation and is a prognostic factor in chronic lymphocytic leukaemia (CLL), where it is associated with an unmutated configuration of the IgVH genes. In this study ZAP‐70 expression was studied by immunohistochemistry in a spectrum of B‐cell lymphoid neoplasms; this staining method was compared with flow cytometry, and the relationship of ZAP‐70 expression to mutational status and prognosis was assessed. 242 tissue samples from 225 patients with B‐cell lymphoid neoplasms arising at different maturational stages were included. Flow cytometry was performed in all CLL cases (n = 52). IgVH mutational status was determined in 25 CLL and 12 mantle cell lymphoma (MCL) patients. ZAP‐70 was positive in 34/52 (65%) CLL, 9/31 (31%) Burkitt's lymphoma, 2/7 (29%) lymphoblastic lymphomas, 3/36 (8%) MCL, 1/23 (4%) marginal zone lymphoma, and 1/45 (2%) diffuse large B‐cell lymphomas, but in none of the 19 follicular lymphomas or the 14 Hodgkin lymphomas. An identical ZAP‐70 pattern was obtained in six patients with simultaneous biopsies from different sites and in 12 patients with sequential biopsies. Immunohistochemistry and flow cytometry gave identical results in 48 the 52 CLLs. All but one ZAP‐70‐positive CLL had IgVH gene in an unmutated configuration, whereas all but one ZAP‐70‐negative CLL had somatically hypermutated IgVH. The 12 MCLs analysed were ZAP‐70 negative regardless of IgVH mutational status (4 mutated, 8 unmutated). ZAP‐70 positive CLL was associated with a shorter overall survival (median time 103 months vs. 293 months, p = 0.01) and a shorter time to disease progression (median time 26 months vs. 60 months, p = 0.01). In conclusion, ZAP‐70 is expressed in several types of B‐cell neoplasm and is easily detected by immunohistochemistry, providing a useful prognostic marker in patients with CLL from whom no other material is available or when other techniques for its assessment cannot be performed. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


  • Open Access

    5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis

    by Esther Titos, Anna Planagumà, Marta Làpez-Parra, Neus Villamor, Rosa Miquel, Wladimiro Jimànez, Vicente Arroyo, Francisca Rivera, Joan Rodàs, Joan Clària


  • Open Access

    Routine use of immunophenotype by flow cytometry in tissues with suspected hematological malignancies

    by Antoni Martínez, Marta Aymerich, Mireia Castillo, Dolors Colomer, Beatriz Bellosillo, Elias Campo, Neus Villamor

    Background: Immunophenotype is an essential parameter in the diagnosis of hematological malignancies. Flow cytometry (FCM) is used in the analysis of bone marrow or peripheral blood samples but is less frequently used in the evaluation of tissue biopsies with suspected hematological malignancies. The aim of this study was to analyze the role of FCM in the diagnosis of biopsies from patients with a suspected hematological disorder.Methods: A total of 422 consecutive biopsies were studied using standard morphology, immunohistochemistry (IHC), and FCM. Results of FCM were obtained in less than 3 h and were interpreted independently from morphology and IHC.Results: A strong correlation between malignant disease and abnormal pattern of FCM was observed (218 of 250) with the exception of Hodgkin disease (P < 0.001). Overall, negative predictive value was 0.52 and positive predictive value was 1. Light chain restriction was observed in 182 of 201 B‐cell lymphoma and in 0 of 142 non–B‐cell disorders by FCM. In contrast, light chain pattern could only be evaluated in 38 of 91 cases by IHC. FCM allowed a rapid diagnosis of infrequent or high‐grade malignancies such as histiocytic sarcoma or T‐lymphoblastic lymphoma. The addition of FCM in the routine study of tissue biopsies facilitates the diagnosis of double pathology in five (1%) patients.Conclusions: FCM is a fast and reliable methodology for phenotyping tissue samples, which easily detects infrequent hematological malignancies, disease‐specific phenotypes and clonality in B‐cell lymphomas. Moreover, the simultaneous recognition of different cell populations allows the diagnosis of composite cell lymphomas, or double pathologies. Cytometry Part B (Clin. Cytometry) 56B:8–15, 2003.


    • 1 March 2003
      • Vol. 88  (3) , 306-14

    CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients.

    by Enric Carreras, Albert Saiz, Pedro Marín, Carmen Martínez, Montserrat Rovira, Neus Villamor, Marta Aymerich, Miquel Lozano, Francesc Fernández-Avilés, Alvaro Urbano-Izpizua, et al.

    Autologous stem cell transplantation (ASCT) is currently being evaluated as a therapy for patients with multiple sclerosis (MS). We report the results of a phase II trial to evaluate feasibility and toxicity of CD34+ selected ASCT (CD34+/ASCT) and treatment results at one year of follow-up. Patients with advanced secondary progressive (SP) or relapsing-remitting (RR) MS and confirmed worsening of the extended disability status scale (EDSS) in the previous year despite interferon or other immunotherapies were included. Peripheral blood stem cells were obtained by leukaphereses after mobilization with cyclophosphamide (Cy) and granulocyte colony-stimulating factor (G-CSF). CD34+ selection was performed by means of an Isolex 300 or CliniMACS device. BCNU, Cy and antithymocyte globulin (ATG) were administered as conditioning regimen. Fifteen patients (9 SPMS and 6 RRMS) with a median EDSS of 6.0 (4.5-6.5) and a median of 3 (1-7) relapses in the previous year were included. Mobilization was unsuccessful in one patient. During mobilization, one patient had a transient neurologic deterioration. The main complication during ASCT were engraftment syndrome, which developed in three patients, CMV reactivation in one, and neurologic deterioration in two patients coinciding with high-fever related to ATG. Hematologic recovery was fast and complete in all cases. At 12 months, the EDSS had improved in three patients, worsened in two and remained stable in nine. Despite withdrawal of all immunosuppressive therapy only two patients had relapses. Magnetic resonance imaging showed disappearance of enhanced T1 lesions but oligoclonal bands persisted in the cerebrospinal fluid of all evaluated cases. CD34+/ASCT using BCNU, Cy and ATG as conditioning regimen has an acceptable toxicity and clearly reduces the progression of MS. Further follow-up is necessary to establish the real impact of this procedure on the long-term evolution of the disease.


  • Open Access

    Rapid Diagnosis of Acute Promyelocytic Leukemia by Analyzing the Immunocytochemical Pattern of the PML Protein With the Monoclonal Antibody PG-M3

    by Neus Villamor, Dolors Costa, Marta Aymerich, Jordi Esteve, Anna Carrió, Maria Rozman, Josep-Lluis Aguilar, Brunangelo Falini, Emili Montserrat, Elias Campo, et al.

    The fusion protein, promyelocytic leukemia–retinoic acid receptor (PML-RAR)alpha, generated by the t(15;17) translocation has an abnormal cellular distribution with colocalization of RARalpha and PML proteins. We analyzed the immunostaining pattern of PML protein using the PGM3 monoclonal antibody directed against the amino terminal portion of PML (retained in wild-type PML and PML-RARalpha fusion protein) in the diagnosis of acute promyelocytic leukemia (APL). In addition, we compared this test with other methods for detecting the PML-RARalpha fusion gene. A normal immunostaining pattern was observed in nonmyeloid disorders and in 78 of 111 acute myeloid leukemias (AMLs). A microgranular pattern was observed in 25 AMLs, all corresponding to APL. These results were concordant with the reverse transcriptase–polymerase chain reaction results for PML-RARalpha fusion gene. Only 1 case positive for the PML-RARalpha transcript showed a normal protein pattern by immunocytochemistry. PML immunostaining was helpful to rapidly differentiate 7 cases with borderline characteristics and to obtain the diagnosis in 2 cases with scarce material. The effectiveness and low cost of this technique support its routine use as a first-line procedure in the differential diagnosis of AML.